Lactobacillus maintains healthy gut mucosa by producing L-Ornithine

Lactobacillus derived L-Orn is a critical factor for lactobacillus mediated RORγt (+) IL-22(+) ILC3 cells and gut mucus formation. L-Orn may be derived from Arg metabolism through ADI pathway in lactobacillus. Lactobacillus derived L-Orn promotes the production of AhR ligand L-Kyn in gut epithelial cells. The AhR ligand L-Kyn produced by gut epithelial cells is responsible for lactobacillus mediated RORγt (+) IL-22(+) ILC3 cells.

Published in Microbiology

Lactobacillus maintains healthy gut  mucosa by producing L-Ornithine
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Gut microbiota play a critical role in maintaining gut homeostasis. They not only regulate gut innate immune but also adaptive immune cells. These immune cell responses are dictated not only via “endogenous” host-derived but also “exogenous” signals such as gut microbiota/their metabolites. Interestingly, many secreted antimicrobial proteins in the gastrointestinal tract may potentially affect the composition of gut microbiota via killing bacteria such as REG3. Thus we investigated the possibility for gut antimicrobial proteins to be involved in gut mucosal homeostasis through the altered microbiota.

We first found that mucus gel remarkably increased in the ileum of REG3Atg mice. Further studies showed that gut REG3A (Reg3a in mouse) promotes the formation of gut mucus layers in the small intestine and colon through RORγt (+) IL-22(+) ILC3 cells.

We next analyzed the composition of gut microbiota and found that the proportion of lactobacilli was high in the ileum and colon of human REG3A tg mice as compared to their control cohoused littermates. We demonstrated that increased lactobacillus in human REG3A tg mice was close to L. Murinus isolates. Previous studies showed that AhR ligand indole-3-aldehyde (IAld) from lactobacillus may contribute to AhR-dependent IL 22 transcription. However, this was not a case for REG3A-associated lactobacillus. We found that lactobacillus derived L-Orn is a critical factor for lactobacillus mediated RORγt (+) IL-22(+) ILC3 cells and gut mucus formation. L-Orn may be derived from Arg metabolism through ADI pathway in lactobacillus. Lactobacillus derived L-Orn promotes the production of AhR ligand L-Kyn in gut epithelial cells. We also found the AhR ligand L-Kyn produced by gut epithelial cells is responsible for lactobacillus mediated RORγt (+) IL-22(+) ILC3 cells. Thus, we demonstrate that lactobacillus may promote the homeostasis of gut mucus layer through producing L-Orn. L-Orn stimulates Trp metabolism to produce AhR ligands in gut epithelial cells, which induce accumulation of RORγt (+) IL-22(+) ILC3 in gut tissues.

For more details, check out the full manuscript here: https://www.nature.com/articles/s42003-019-0424-4

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Microbiology
Life Sciences > Biological Sciences > Microbiology

Related Collections

With Collections, you can get published faster and increase your visibility.

DNA repair and human disease

This cross-journal Collection between Nature Communications, Communications Biology and Scientific Reports welcomes submissions on the mechanisms of DNA repair using multiple modelling systems and the applications of DNA repair mechanisms in human disease diagnosis and treatment.

Publishing Model: Hybrid

Deadline: Oct 31, 2026

Cell death and inflammatory signalling

The editor invite submissions of original biological and clinical research focusing on the finely-tuned control of non-immune and immune cell death, the coordinated regulation of programmed cell death and the resulted immune response in health and disease, and the selective targeting of cell death regulatory molecules as a therapeutic solution for chronic inflammatory disorders.

Publishing Model: Hybrid

Deadline: Oct 28, 2026